Accesswire
19 Jun 2026, 22:00 UTC · 11w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Onco-Innovations successfully completed a 300g scale-up batch of the API for its drug candidate ONC010 with 99.3% purity. — Proving manufacturing scalability and high purity is a critical technical derisking milestone necessary to move toward human clinical trials.
+0.60The completed API batch will support ongoing IND-enabling activities and the path toward First-in-Human evaluation. — Directly advances the timeline for regulatory filing (IND), bringing the company closer to the value-inflection point of clinical data.
+0.40The company appointed Dave Antony as the new Chief Financial Officer and Corporate Secretary, replacing Nico Mah. — C-suite changes are standard operational updates and generally have neutral to low impact unless accompanied by negative context.
+0.10Which stocks this story touches
Continue reading
5 related stories
Search tags
The company achieved a significant manufacturing milestone with high-purity API scale-up for its lead drug candidate and appointed a new CFO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
18h ago
